Effects of cefodizime on non-specific immune functions in patients with multiple myeloma.
The effects of cefodizime (CDZ) on non-specific immunity in patients with multiple myeloma were studied in a randomized, placebo-controlled trial. A total of 51 patients with newly diagnosed multiple myeloma were admitted to the study, 27 of whom received CDZ 2 gi.v. once daily for seven days and 24 ascorbic acid 1 g daily i.v. for one week. Granulocyte chemotaxis, neutrophil biochemiluminescence and phagocytosis were determined at baseline, and at 48 h after the last dose. At baseline, chemiluminescence, phagocytosis and, to a lesser extent, granulocyte chemotaxis were diminished in both patient groups compared to healthy volunteers. After treatment, a significant increase in chemiluminescence and phagocytosis was observed in the CDZ group, while a slight increase in granulocyte chemotaxis did not reach statistical significance. No changes were observed in the control group. It is concluded that CDZ enhanced non-specific immune mechanisms in patients with multiple myeloma.
Dammacco
F
F
Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Italy.
Benvestito
S
S
D000368:Aged; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D007155:Immunologic Factors / Q000494:pharmacology*; D008163:Luminescent Measurements; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000276:immunology*; D009504:Neutrophils / Q000502:physiology
D007155:Immunologic Factors; D002439:Cefotaxime; C033356:cefodizime